WO2002086084B1 - Sequence characteristics of bladder cancer - Google Patents
Sequence characteristics of bladder cancerInfo
- Publication number
- WO2002086084B1 WO2002086084B1 PCT/US2002/012774 US0212774W WO02086084B1 WO 2002086084 B1 WO2002086084 B1 WO 2002086084B1 US 0212774 W US0212774 W US 0212774W WO 02086084 B1 WO02086084 B1 WO 02086084B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotides
- expression
- polypeptide
- level
- polynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of a least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering a patient a therapeutically effective amount of chemical compound are also provided.
Claims
AMENDED CLAIMS
[received by the International Bureau on 27 February 2003 (27.02.03) claims 26 to 29 added];
1. A method of diagnosing bladder canceϊ in a subject which comprises the step of; determining, in a sample from the .ubjeσt, the level of expression of at least two p )lypeptide- encoding polynucleotides, wherein a higher evel of expression of the polynucleotides compared to th -. level of expression of che polynucleotides in a sub ect free of bladder cancer is indicative of bladder ca icer, and wherein the polypeptide-encoding polynucleotic s are selected from the group consisting of: a. the polynucleotides having sec jences represented by SEQ ID NOS: 57, 56, one of ■ 1 or 42, 45, 61, 4S, SI, 47, 55, 58, 43, 44, 53, 41, 60, 59, 52, 46 and 50; b. polynucleotides having sequen :eε that differ from the polynucleotides in (a) , without changing the polypeptides encoded thereby; and c. polynucleotides which are at least 70% homologous to the polynucleotides of (a)
2. The method according to claim 1, wherein said determining step includes determining the level of expref sion of at least: two polypeptide-encoding polynucleotide =, wherein che polypeptide-encoding polynucleotides a 'e selected from the group consisting of the polynucleot: 3es having sequences represented by SEQ ID NOS: 57, 56, one of 41 or 42, 45, 61, 48, 51, 47, 55, 58, 43, 44, 53, 49, 60, 59, 52, 46 and 50;
3. The method according to claim 2, wherein said determining step includes determining the level of expre ssion of at least one
polypeptide-encoding polynucleotide whe. sin the polypeptide- encoding polynucleotide comprises a po_l nucleotide selected from the group consisting of the polyn icleo ides listed in cable 6.
The method according to claim 1, wherein the determining step includes using mRNA from an expressed ge e to hybridize to at least two polynucleotides selected from the group consisting of the polynucleotides having sequences epresenced by SEQ ID NOS: 57, 56, one of 41 or 42, 45, 61, 48 51, 47, 55, 58, 43, 44, 53, 49, 60 , 59 , 52, 46 and 50.
The method according to claim l, whereά I the analysing step includes the step using RT-PCR technolo; y.
The method according to claim 1, wherej l the analyzing step includes the step of using a specific ai tibody co detect the presence of a polypeptide encoded by sa. d polynucleotide. A method of diagnosis of stageTa i transitional cell carcinoma in a patient which comprises: decermining, in a sample from tl ≥ patient, the level of expression of at least two ) olypeptide- encoding polynucleotides, wherein a highe- level of expression of the polynucleotides compart d to the level of expression of the polynucleotide, in a patient free of transitional cell carcinoma is i- dicative of scageϊa, and wherein the polypeptide- enc> ding polynucleotides are selected from the group consisting of: a. the polynucleotides having equences represented by SEQ ID NOS: 57, 56, one Of 41 or 42, 45, 61, 48, 51, 47, 55, 58, 43, 44 53, 49, 60 , 59, 52, 46 and 50; b. polynucleotides having se juenσes that differ f om the polynucleotides in (a) , without changing the polypeptides encoded tl areby,- and
113
c. polynucleotides which are at least 70% homologous to the polynucleotides of ( ;) .
8. The method according to claim 7, when ϋin said determining step includes determining the level of expression of at lease one polypeptide-encoding polynu< ieotide, wherein the polypeptide-encoding polynucleotide e icodes Keratin 13.
9. A method of differential diagnot is of stageTl in transitional cell carcinoma in a pati :nt which comprises: determining, in a sample from tl ≥ patient, the level of expression of at least two polypeptide-encoding polynucleotides, wherein a higher level of expression of the polynucleotides compare i to the level of expression of the polynucleotide s in a patient free of transitional cell carcinom is indicative of stageTl, and wherein the polypepcide-enαoding polynucleotides are selected from the group consisting of: a. the polynucleotides having , equences represented by SEQ ID NOS: 57, 56, one f 41 or 42, 45, 61, 48, 51, 47, 55, 58, 43, 44, 53, 49, 60, 59, 52, 46 and 50; b. polynucleotides having se [uences thac differ from the polynucleotides in (a) , without changing the polypeptides encoded tl- reby; and c. polynucleotides which are at least 70% homologous to the polynucleotides of I ) .
1,0. An isolated polynucleotide which σomp. Lses a polynucleocide selected from the group consisting essentially of: a. The polynucleotides listed Tables 3, 4, and 6;
114
21. A gene therapy vehicle for deliver ng a polynucleotide according to claim 11 to a su iject, whereby the polynucleotide is expressed in the -.arget cells of the subject.
22. An isolated antisense oligonucleotid σomplemencary to a unique sequence within the polynuσj sotide according to claim 10.
23. An isolated ancisense oligonucleotide complementary to the polynucleotide according to claim 11.
24. The method according to claim 1, where .n the bladder cancer is transitional cell carcinoma.
25. The method according to claim 18, therein the bladder cancer is transitional cell carcinoma
26. The method of claim 1, wherein the It vel of expression of at least three polypeptide-encoding polynucleotides is determined.
27. The method of claim 2, wherein the lc vel of expression of at least three polypepride-encodinc polynucleotides is determined.
28. The method of claim 1, wherein the pol Tiuσleotides of group
(a) are selected from polynuσleotic es having sequences represented by SEQ ID NOS: 57, 56, one of 41 or 42, and 45.
29. The method of claim 2 wherein the pol- nucleotides of group
(a) are selected from polynucleoti< es having sequences represented by SEQ ID NOS: 57, 56, o e of 41 or 42, and 45.
115
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002338431A AU2002338431A1 (en) | 2001-04-04 | 2002-04-04 | Sequence characteristics of bladder cancer |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/825,682 US6998232B1 (en) | 1999-09-27 | 2001-04-04 | Methods of diagnosing bladder cancer |
| US09/825,682 | 2001-04-04 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2002086084A2 WO2002086084A2 (en) | 2002-10-31 |
| WO2002086084A3 WO2002086084A3 (en) | 2003-03-27 |
| WO2002086084B1 true WO2002086084B1 (en) | 2003-11-20 |
Family
ID=25244665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2002/012774 WO2002086084A2 (en) | 2001-04-04 | 2002-04-04 | Sequence characteristics of bladder cancer |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002338431A1 (en) |
| WO (1) | WO2002086084A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
| DE10309729A1 (en) * | 2003-02-26 | 2004-09-16 | Hinzmann, Bernd, Dr. | Human nucleic acid sequences from bladder cancer |
| KR20070051286A (en) | 2004-07-23 | 2007-05-17 | 퍼시픽 에지 바이오테크놀로지 엘티디. | Urine markers for detection of bladder cancer |
| NZ545243A (en) | 2006-02-10 | 2009-07-31 | Pacific Edge Biotechnology Ltd | Urine gene expression ratios for detection of cancer |
| TWI814373B (en) | 2010-09-29 | 2023-09-01 | 美商艾澤西公司 | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2139540C1 (en) * | 1991-01-15 | 1999-10-10 | Биоти Терапис Лтд. | Method of detection of malignancy |
| US6207380B1 (en) * | 1997-09-15 | 2001-03-27 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the urinary tract |
| WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
| WO2001022864A2 (en) * | 1999-09-27 | 2001-04-05 | Quark Biotech, Inc. | Sequences characteristic of bladder cancer |
-
2002
- 2002-04-04 WO PCT/US2002/012774 patent/WO2002086084A2/en not_active Application Discontinuation
- 2002-04-04 AU AU2002338431A patent/AU2002338431A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002086084A3 (en) | 2003-03-27 |
| WO2002086084A2 (en) | 2002-10-31 |
| AU2002338431A1 (en) | 2002-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102391812B1 (en) | Nucleic acid molecules for reducing PAPD5 or PAPD7 mRNA to treat hepatitis B infection | |
| Tölg et al. | Splicing choice from ten variant exons establishes CD44 variability | |
| Bièche et al. | Poly (ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. | |
| US6953670B2 (en) | Methods for identifying compounds capable of supplementing the biological activity of leptin | |
| WO2002044413A3 (en) | Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates | |
| CA2323525A1 (en) | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis | |
| RU2004116308A (en) | MORPHOGENIC BONE PROTEINS (BMP), BMP RECEPTORS AND BMP-BINDING PROTEINS AND THEIR APPLICATION FOR DIAGNOSIS AND TREATMENT OF GLAUCOMA | |
| JP2006500949A5 (en) | ||
| CN101688239A (en) | The early detection of colorectal carcinoma and prognosis | |
| CA2439313A1 (en) | Method of determining dihydropyrimidine dehydrogenase gene expression | |
| EP2199411A1 (en) | Epigenetic markers for the identification of CD3 positive T-lymphocytes | |
| JP2012501164A5 (en) | ||
| WO1998003679A1 (en) | Method for the diagnosis of spinocerebellar ataxia type 2 and primers therefor | |
| WO1997026370A1 (en) | Leptin receptor variants | |
| JP2007236253A (en) | Method for detecting disease or disease marker | |
| WO2004018709A3 (en) | Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease | |
| WO2002086084B1 (en) | Sequence characteristics of bladder cancer | |
| JP2006518186A5 (en) | ||
| CA2263895A1 (en) | Therapeutic and diagnostic applications of perlecan domain i splice variants | |
| US6627401B2 (en) | Method for detecting a single nucleotide polymorphism in p21waf1/cip1 gene as an indicator of risk of esophageal cancer | |
| KR20230154009A (en) | Diagnosis and risk assessment of head and neck cancer | |
| GANGULY et al. | Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations | |
| Justice et al. | Phylogenetic analysis of the Friedreich ataxia GAA trinucleotide repeat | |
| WO2003072813A3 (en) | Single nucleotide polymorphisms predicting adverse drug reactions and medication efficacy | |
| CA2441314A1 (en) | Quantitative diagnostic analysis of hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| B | Later publication of amended claims |
Free format text: 20030227 |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |